Results 61 to 70 of about 28,869 (265)

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

A Phase 2b randomised, controlled, partially blinded trial of the HIV Nucleoside Reverse Transcriptase Inhibitor BMS-986001 (AI467003): Weeks 24 and 48 Efficacy, Safety, Bone and Metabolic Results [PDF]

, 2016
Background BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects.
Avihingsanon, Anchalee, Echevarría, Juan, Gupta, Samir K., Hanna, George J., Joshi, Samit R., Lataillade, Max, Lombaard, John, McComsey, Grace A., Orrell, Catherine, Osiyemi, Olayemi, Ray, Neelanjana, Santoscoy, Mario, Stock, David A.   +12 more
core   +1 more source

Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials

International Journal of Infectious Diseases, 2020
Background: Tenofovir disoproxil fumarate (TDF) can cause renal and bone toxicity, which is associated with high plasma tenofovir concentrations in antiretroviral treatment of HIV-1 infected patients.
Xingbao Tao, Yanqiu Lu, Yihong Zhou, Lvlang Zhang, Yaokai Chen   +4 more
doaj   +1 more source

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method

Frontiers in Pharmacology, 2021
Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV) that has been approved for the treatment of chronic hepatitis B virus (HBV) infection.
Na Yang, Guanlun Zhou, Xiaoliang Cheng, Jun He, Yan Chen, Chao Chen, Meijuan Li, Jiajia Ge, Min Wang, Tianqi Zhang, Weihong Ge, Huaijun Zhu, Guorong Han   +12 more
doaj   +1 more source

Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes in patients with chronic hepatitis B virus (HBV) infection based on studies predominantly in Asian populations. We assessed real‐world associations between HBsAg loss and long‐term clinical outcomes in a diverse US population with chronic HBV infection. This
Myriam Drysdale, Rose Chang, Shuang Wang, Anna Coutinho, Vera Gielen, Theo Man, Rui Song, Mei Sheng Duh, Mandana Khalili, Dickens Theodore   +9 more
wiley   +1 more source

Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: From treatment to prevention [PDF]

, 2013
The HIV epidemic continues unabated, with no highly effective vaccine and no cure. Each new infection has significant economic, social and human costs and prevention efforts are now as great a priority as global antiretroviral therapy (ART) scale up ...
A Bedri, A Calmy, A Coovadia, A Coovadia, A De Luca, A Hill, A Kunz, A Moorthy, A Moorthy, A Shibata, A Zolopa, AN Phillips, AY Liu, BE Nichols, BE Nichols, BG Brenner, BR Yehia, C Laurent, C Pretorius, C Unge, C Unge, C Zeh, CA Boucher, CB Hurt, CJ Hoffmann, CL Townsend, CS Chasela, D Descamps, D Frentz, D Frentz, D Persaud, DA van de Vijver, DA van de Vijver, DADS Group, DAMC Van de vijver, David A M C Van de Vijver, DC Vissers, DE Bennett, DJ McColl, E Arrive, E Bendavid, E Mills, EM Connor, ER Cooper, ES Daar, F Doualla-Bell, F Tanser, F van Leth, F van Leth, FA Frankel, FDA, FJ Palella Jr, G Jourdain, G Jourdain, GL Melikian, GN Nikolenko, H Sunpath, HM Coovadia, I de Vincenzi, I Thior, J Bor, J Fogel, J Marrazzo, J Mermin, J Mermin, J Ren, J Vercauteren, JA Hontelez, JA McIntyre, JB Nachega, JE Gallant, JE Gallant, JM Baeten, JM Baeten, JM Fogel, JM Whitcomb, JO Kahn, Joint United Nations Programme on HIV/AIDS (UNAIDS), JW Eaton, KA Delviks-Frankenberry, KN Althoff, L Ryom, L Van Damme, L Wittkop, LA Guay, M Lallemant, M Mirochnick, MA Fischl, MA Thompson, MA Wainberg, Mark A Wainberg, MC Hosseinipour, MC Thigpen, MD Miller, MS Cohen, N Ford, N Shaffer, N Sood, NA Martinson, NA Wade, NE Mackie, NI Kumwenda, P Mugyenyi, PR Meyer, Q Abdool Karim, R Granich, R Gupta, R Kaplan, Ravindra K Gupta, RE Barth, RF Schinazi, RF Schinazi, RK Gupta, RK Gupta, RL Hamers, RL Hamers, RL Shapiro, RM Granich, RM Grant, RM Gulick, RM Mainardes, RS Veazey, S Lockman, S Loubser, S Rosen, S Staszewski, S Staszewski, S Sungkanuparph, S Yerly, SH Eshleman, SH Yap, Sheetal Manicklal, SL Spruance, T Flys, U CHIC, UL Abbas, UM Parikh, UNAIDS, UNAIDS, V Cambiano, V von Wyl, VD Lima, VS Gill, WHO, WHO, Z Shubber   +145 more
core   +4 more sources

A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions

AIDS Research and Therapy
Introduction Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e.
Sonya Krishnan, Marina B. Martinez Rivera, Christopher K. Lippincott, Maunank Shah   +3 more
doaj   +1 more source

PLA2R‐Positive Membranous Nephropathy and AA Amyloidosis in an Ethiopian Patient With Chronic Hepatitis B: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT The coexistence of primary phospholipase A2 receptor positive membranous nephropathy and AA amyloidosis in a patient with chronic hepatitis B is an exceedingly rare triad presenting a profound diagnostic and therapeutic challenge. A 38‐year‐old Ethiopian man with nephrotic syndrome and chronic hepatitis B had dual pathology on renal biopsy ...
Betelhem Abreham, Leja Hamza, Azeb Kebede, Daniel Rebuma Bekele, Zekarias Amdemariam   +4 more
wiley   +1 more source

Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consort

The Lancet HIV
BACKGROUND Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight gain in several clinical trials and observational cohorts.
D. Byonanebye, M. Polizzotto, Fernando Maltez, Andri Rauch, K. Grabmeier-Pfistershammer, F. Wit, S. de Wit, A. Castagna, A. d’Arminio Monforte, C. Mussini, J. Wasmuth, E. Fontas, I. Abela, Mario Sarcletti, L. Bansi-Matharu, N. Jaschinski, Lars Peters, Sean R Hosein, V. Vannappagari, Cal Cohen, Emiliano Bissio, A. Mocroft, M. Law, L. Ryom, K. Petoumenos   +24 more
semanticscholar   +1 more source

Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. [PDF]

, 2016
There have been dramatic advancements in the treatment of chronic hepatitis C (HCV) infection. This is largely due to the approval of several direct-acting antiviral agents (DAAs) from a variety of medication classes with novel mechanisms of action ...
Bidell, Monique R, Faragon, John, McLaughlin, Milena, Morse, Caroline, Patel, Nimish   +4 more
core   +2 more sources